Company Overview - Newmont Corporation operates as a gold producer and explores for copper, silver, lead, zinc, and other metals, with operations in the United States and internationally [3]. Market Position and Price Target - Newmont Corporation's share was trading at $122.13 as of February 20th, with a trailing P/E of 15.66 and a forward P/E of 15.82 [1]. - The target price for Newmont is set at $126.88, indicating a potential 4.2% increase from the previous close of $121.80 [3]. Financial Performance - Newmont reported a strong Q3 2025 performance, with earnings per share exceeding estimates by 32.56% and record free cash flow of $1.6 billion, alongside near-zero net debt [4]. - The company has a significantly strengthened balance sheet and capital flexibility, enhancing its operational capabilities [4]. Production and Operational Catalysts - The Ahafo North Mine has reached commercial production, which is expected to improve efficiency and contribute significantly to future output [4]. Analyst Sentiment and Stock Performance - Analyst consensus ratings for Newmont are at Buy, with a price target of $125, supported by a recent upgrade from RBC Capital Markets that contributed to a 4.8% increase in stock price [5]. - The stock is trading above key moving averages and has shown strong 20-day returns of 8.29%, indicating continued upward momentum [5]. Industry Outlook - Major banks, including Wells Fargo and JPMorgan Chase, have raised long-term gold price forecasts to approximately $6,100–$6,300 by 2026, reinforcing expectations of sustained profitability in the gold mining industry [4].

Core Thesis - Jefferson Capital, Inc. (JCAP) is viewed negatively due to its underlying unit economics and capital-intensive business model, despite attractive headline metrics [1][8]. Company Overview - Jefferson Capital is a newly public company that specializes in purchasing charged-off consumer debt, with a majority ownership of 67% by J.C. Flowers [2]. - The company targets to buy defaulted loan portfolios at approximately 5–6% of their face value, aiming for a 2x gross recovery multiple through various collection methods [2]. Financial Metrics - JCAP's share price was $22.07 as of February 11th, with a trailing P/E ratio of 9.26 [1]. - The company has reported a levered free cash flow yield of around 20% and a year-over-year operating income growth of 39% [3]. Unit Economics - Mature vintages from 2017–2020 achieved about 2x gross recoveries and over 27% IRRs before operating costs, but cash operating expenses average around 40% of collections [4]. - After accounting for these costs, the implied unlevered returns drop to the high single digits [4]. Valuation Concerns - Even with a 60% after-tax recovery margin, modeled equity values are estimated between $300 million and $400 million, after deducting $1.3–1.4 billion in liabilities, indicating limited upside compared to current valuations [5]. - Although JCAP appears inexpensive relative to peers like Encore Capital and PRA Group, its capital-intensive model resembles a capital-recycling operation rather than a true compounding business [5]. Reinvestment and Governance - Nearly all excess cash flow must be reinvested to maintain portfolio size, as demonstrated by a $300 million loan book purchase in late 2025 [6]. - Sustainable through-cycle return on equity (ROE) is likely in the range of 12–13%, and governance is heavily influenced by its private equity sponsor, suggesting a valuation closer to book value rather than its current premium [6].

Company Overview - LeMaitre Vascular, Inc. (LMAT) is a leading owner-operator in the peripheral vascular device market with a market cap of $1.9 billion, designing and marketing over 100 specialized devices for vascular procedures outside the heart and brain [2] - The company has grown through a disciplined roll-up strategy, acquiring more than 30 subsidiaries, which allows it to leverage a fragmented market and achieve operational synergies [3] Financial Performance - LeMaitre has historically achieved revenue growth at a CAGR of 12–15% and EPS growth at a CAGR of 19–21%, with forward growth estimates remaining attractive [5] - The company enjoys a 71% gross margin, 21% return on invested capital (ROIC), and strong free cash flow conversion, indicating robust financial health [4] Competitive Advantage - LeMaitre benefits from a durable competitive advantage due to its highly specialized products, regulatory barriers, and strong relationships with surgeons [4] - The founder-led management under George W. LeMaitre aligns shareholder interests with long-term growth, having delivered over 1,500% returns since the 2006 IPO [3] Growth Drivers - The company has dual growth engines: organic demand driven by an aging global population and minimally invasive surgery trends, alongside inorganic growth through acquisitions [4] - Valuation metrics suggest reasonable upside, trading below its 10-year average forward P/E, with expected returns of 11–16% per year [5] Investment Thesis - LeMaitre Vascular exemplifies a high-quality, patient, and compounding business in a resilient and growing medical device niche, supported by strong fundamentals and disciplined capital allocation [5] - The Total Quality Score of 8/10 reflects its status as an exceptional investment opportunity [5]

Core Thesis - Littelfuse, Inc. is being reexamined for its inclusion in QVI's Real-Time Stock Picks due to concerns over its weakening financial performance despite a strong industry position [2][4]. Company Overview - Littelfuse, Inc. operates in the information technology sector as a small-cap electronics manufacturer, supplying critical components such as fuses, sensors, switches, relays, and power modules across various segments including electronics, transportation, and industrial [2]. - The company was added to QVI's portfolio in 2022 at a cost basis of $199.54 per share, with its stock trading at $253.56 as of December 1st [2]. Financial Performance - Revenue growth has lagged behind the S&P 500 over both one-year and five-year periods, raising concerns about management execution [3]. - Littelfuse's net margin is in the mid-single digits, indicating structurally lower gross margins compared to the broader market [3]. - Returns on equity and invested capital have fallen below acceptable thresholds, with ROIC not exceeding the cost of capital, suggesting inefficiencies in capital deployment [4]. - Owners' earnings have underperformed expectations, showing negative EPS growth over the past year and only low single-digit growth over five years, although free cash flow growth improves long-term owners' earnings [4]. Market Position and Valuation - The company has a century-long operating history and strong customer relationships, which contribute to its narrow moat rating by Morningstar [3]. - QVI maintains a bullish view on the company's value proposition due to the resilience of technology-oriented component suppliers, despite the deteriorating fundamentals [4].

Core Thesis - Verra Mobility Corporation (VRRM) is positioned as a compelling investment opportunity due to its strong market presence, growth potential, and underappreciated contracts, particularly with New York City [1][4]. Company Overview - Verra Mobility Corporation operates in smart mobility technology solutions across the United States, Australia, Europe, and Canada, focusing on two main segments: Commercial Services (CS) and Government Solutions (GS) [2]. - The company holds a market share of over 90% in CS and 70% in GS, indicating strong competitive positioning [3]. Segment Performance - CS is experiencing high-single-digit growth driven by the rise of cashless tolling and increased toll-road usage, while GS growth is accelerating due to new legislation and the expansion of automated traffic enforcement programs [3]. - The largest customer, New York City, contributes $139 million in annual service revenue, with a recently secured five-year contract valued at $963 million, which includes a 25% increase in recurring service revenue compared to 2024 [3]. Financial Outlook - The consolidated business is projected to generate significant free cash flow, with an estimated $266 million by 2028, and the stock is currently trading at a forward free cash flow yield of approximately 5% [4]. - The anticipated growth in both CS and GS segments is expected to exceed consensus estimates for FY26 and FY27, supported by stronger-than-expected throughput and travel demand [4]. Investment Catalysts - Near-term catalysts include the official announcement of the NYC contract and potential upgrades from analysts, which could further enhance the stock's appeal [4].

Core Thesis - The article presents a bullish thesis for Merck (MRK), highlighting its strong product portfolio including Keytruda, Gardasil, and Noxafil [1]. Company Attributes - Merck is characterized by several bullish attributes that position it favorably in the pharmaceutical industry [1]. Investment Strategy - The article reflects an interest in both long and short trading strategies, indicating a focus on building financial assets for retirement [1].

Core Thesis - Pfizer Inc. is viewed positively due to its strong financials, robust cash flow, and potential for capital appreciation despite recent revenue normalization post-COVID [2][5]. Financial Performance - Pfizer's revenue has decreased from approximately $100 billion in 2022 to $58 billion in 2023, but is projected to rebound to around $64 billion by 2025 due to new drug launches [2]. - The company maintains strong profitability with operating margins near 28% and net margins exceeding 35% [2]. - Pfizer generates over $18 billion in annual free cash flow, which supports dividends, share buybacks, and R&D without reliance on capital markets [3]. - The stock offers a dividend yield near 6.7%, with a historical record of not cutting dividends since the 1940s [3]. Valuation Metrics - Pfizer's trailing and forward P/E ratios are 12.78 and 7.74 respectively, indicating a valuation below the industry average [1][2]. - If the dividend yield reverts to its historical average of 4%, Pfizer shares could imply a price range of $42–$45, suggesting significant upside potential [3]. Technical Analysis - Technical indicators show a medium-term bullish trend with a higher-low/higher-high structure since May, positive RSI and MACD momentum [4]. - Key retracement support is identified around $25.10–$25.20, providing a disciplined entry point for investors [4]. - Upside targets are set at $27.50 and $29, with a stop-loss below $24 to mitigate downside risk [4]. Strategic Outlook - The company has a strong pipeline of new therapies and has engaged in strategic M&A with Seagen, which supports its long-term growth prospects [5]. - Despite a 17% depreciation in stock value since the last coverage, the overall investment thesis remains intact due to attractive cash flow and valuation metrics [5].

Core Viewpoint - The article discusses the conditions under which the author would reconsider their bullish investment thesis, emphasizing the importance of understanding international market dynamics [1]. Group 1 - High-quality market opinions require a comprehensive understanding of international factors [1].

Core Thesis - Taseko Mines Limited (TGB) is viewed positively due to its strong asset base and growth potential, particularly from the Florence in-situ copper project, which is expected to significantly enhance the company's EBITDA and production capacity [1][5]. Company Overview - Taseko Mines is a Canadian-based, US-listed junior copper miner with one producing asset (Gibraltar mine), one near-term project (Florence), and three large-scale greenfield developments [2]. - The Gibraltar mine has a 32-year mine life and produced 106 million pounds of copper in 2024 at a cash cost of $2.30 per pound, with a projected increase to 120 million pounds in 2025 [2]. Florence Project - The Florence project, with buildout costs of $235 million, is expected to produce 85 million pounds annually at a cash cost of $1.11 per pound, placing it in the first quartile of the global cost curve [3]. - The project is anticipated to begin ramping up in Q4 2025 and contribute approximately $325 million in EBITDA, in addition to Gibraltar's $250 million [3]. Long-term Growth Potential - Taseko has three greenfield projects in British Columbia: New Prosperity, Yellowhead, and Aley, with Yellowhead prioritized for development due to its superior economics [4]. - By 2027, TGB's projected copper production of 88,000 tons is valued at $12,841 per ton, significantly lower than peers, suggesting a potential for a 50%+ upside in stock valuation if copper prices rise [4].